Open access peer-reviewed Edited Volume

Tumor Angiogenesis

Ke Xu

Tianjin Medical University General Hospital

A pioneering researcher in cancer metastasis and chemoresistance, an active member of the American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology. Professor Ke Xu carried out his research fellowship at Imperial College London (UK), investigating gene targeting and lung cancer.


Angiogenic Factors Cytokines Tumor Microenvironment Vascular Endothelial Cells Tumor Cells Blood Vessels Liquid Biopsy Therapeutic Targets Tumor Microenvironment Invasion Signaling Pathways Antibodies

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

The tumor is one of the leading causes of death worldwide. Tumor angiogenesis, the development, and the growth of blood vessels play a crucial role in tumor progression. The hypothesis of tumor angiogenesis was first proposed by Dr. Judah Folkman in 1971, and tumor angiogenesis becomes one of the most important fields in cancer research. When the tumors mass reaches a size of 0.2 -2.0 mm in diameter, the tumor becomes hypoxic and lacks nutrients, which limits tumor growth. This stimulates angiogenesis, and the newly formed blood vessels deliver nutrients and remove metabolic waste from tumor cells. Neovascularization involves several mechanisms, including sprouting angiogenesis, intussusceptive angiogenesis, vasculogenesis, recruitment of endothelial progenitor cells, vascular mimicry, trans-differentiation of cancer stem cells. The tumor microenvironment promotes tumor angiogenesis via angiogenic factors, cytokines, non-coding RNA, and hypoxia. Tumor angiogenesis plays a vital role in tumor growth, in particular, in tumor invasion and metastasis. Targeting tumor angiogenesis becomes a promising strategy for cancer treatment. Many tumor angiogenesis-targeted drugs have been approved by FDA, such as Bevacizumab, Ramucirumab, Sorafenib, Cabozantinib.

This book will provide readers with the advance of state-of-the-art research on tumor angiogenesis, and the latest approaches to tumor angiogenesis-based targeting therapy.

Publishing process

Book initiated and editor appointed

Date completed: October 29th 2021

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: December 23rd 2021

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: February 21st 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: May 12th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: July 11th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Ke Xu

Tianjin Medical University General Hospital

Professor Ke Xu earned his BSc degree in Microbiology from Nankai University (China), and his Ph.D. degree in Cell and Molecular Biology from University of Essex (UK). He completed his postdoctoral training at the Institute of Cancer Research (UK), studying on the induction of leukemia cell apoptosis and differentiation. Professor Ke Xu carried out his research fellowship at Imperial College London (UK), investigating gene targeting and lung cancer. He joined the Tianjin Lung Cancer Institute of Tianjin Medical University General Hospital (China) in 2007 as a principle investigator to establish an independent research group, studying the molecular mechanism of metastasis and chemoresistance of lung cancer. He also develops novel chemical compounds to interfere with key cancer promoting pathways. Professor Ke Xu is an active member of American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, Chinese Anti-Cancer Association, Chinese Society for Cell Biology, and Chinese Pharmaceutical Association.

View profile

Book chapters authored 0

Books edited 2

Introducing your Author Service Manager

Mrs. Elena Vracaric

Ask a question

Book will be abstracted and indexed in